Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDialight Regulatory News (DIA)

Share Price Information for Dialight (DIA)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 160.50
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 17.00 (11.184%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 160.50
DIA Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

16 Mar 2018 15:40

RNS Number : 0403I
Dialight PLC
16 March 2018
 

Dialight plc ("Company")

 

Director/PDMR Shareholdings

16 March 2018

 

Options and Awards under the Dialight plc 2014 Performance Share Plan ("PSP")

 

On 16 March 2018 the under-mentioned Director/Person Discharging Managerial Responsibility, was granted a nil cost option which entitled her to receive ordinary shares of 1.89 pence each in the Company in accordance with the rules of the PSP.

 

Name

Number of Options granted under the PSP

Total number of shares over which incentive awards in the PSP held following notification

% of issued class

Fariyal Khanbabi (Director)

50,862

159,015

0.489

 

On 16 March 2018 the under-mentioned Director/Persons Discharging Managerial Responsibility, were granted a conditional award, which entitled them to acquire ordinary shares of 1.89 pence each in the Company in accordance with the rules of the PSP.

 

Name

Number of shares awarded under the PSP

Total number of shares over which incentive awards in the PSP held following notification

% of issued class

Martin L. Rapp

(Director)

104,280

104,280

0.321

Luis Ramirez

21,160

24,768

0.076

Rizwan Ahmad

7,220

22,421

0.069

Michael Schratz

7,886

23,860

0.073

Matt Boudiette

11,740

19,744

0.061

 

Options and awards will normally vest on the third anniversary of grant subject to continued employment. In relation to the awards made to Martin L. Rapp and Fariyal Khanbabi only, the award and option (respectively) are subject to the satisfaction of two performance conditions as set out below.

25% of an option or award is measured against the Company's total shareholder return ("TSR") over the three year period relative to the FTSE SmallCap Index (excluding investment trusts) ("TSR Performance Condition"). The remaining 75% of the option or award is measured against the Company's earnings per share ("EPS") in 2020 ("EPS Performance Condition").

TSR Performance Condition

No part of an option or award subject to the TSR Performance Condition shall vest if the percentage increase in the Company's TSR is below the percentage increase in the TSR of the comparator index. 25% of the ordinary shares under an option or award subject to the TSR Performance Condition will vest if the percentage increase in the Company's TSR is equal to the percentage increase in the TSR of the comparator index, rising on a straight-line basis to 100% vesting if the percentage increase in the Company's TSR is equal to or exceeds the increase in the TSR of the index plus 10% per annum.

EPS Performance Condition

No part of an option or award subject to the EPS Performance Condition will vest if the Company's 2020 EPS is below 45 pence, 25% of the option or award subject to the EPS Performance Condition will vest if the Company's 2020 EPS equals 45 pence, rising on a straight-line basis to 100% vesting if the Company's 2020 EPS equals or exceeds 60 pence.

No consideration was paid for the grant of these options and awards and no consideration is due to be paid by the participant on the vesting of these options and awards. On vesting, options will be exercisable between 16 March 2021 and 16 March 2023.

Holding Period

A mandatory two-year post-vesting holding period applies to the PSP options/awards granted to Martin L. Rapp and Fariyal Khanbabi.

 

The details of the awards and options are as follows:

 

1.

Details of the person discharging managerial responsibilities/person closely associated

(a)

Name

i. Martin L. Rapp

ii. Fariyal Khanbabi

iii. Luis Ramirez

iv. Rizwan Ahmad

v. Michael Schratz

vi. Matt Boudiette

2.

Reason for the notification

(a)

Position/status

i. Group Chief Executive Officer

ii. Group Finance Director

iii. Chief Operating Officer

iv. VP, Power and Control Systems

v. VP, Sales and Marketing

vi. VP, Signals and Components

(b)

Initial notification/ Amendment

Initial notification

3.

Details of the issuer

(a)

Name

Dialight plc

(b)

LEI

2138001AD31KKD29Z495

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

(a)

Description of the Financial Instrument

Ordinary shares of £0.0189 each

(b)

Identification code of the Financial Instrument

GB0033057794

(c)

Nature of the transaction

Grant of share options/awards under the Dialight plc PSP equity scheme

(d)

Price(s) and volume(s)

Price(s)

Volume(s)

i. Nil

ii. Nil

iii. Nil

iv. Nil

v. Nil

vi. Nil

i. 104,280

ii. 50,862

iii. 21,160

iv. 7,220

v. 7,886

vi. 11,740

(e)

Aggregated information

- Aggregated volume

- Price

 

203,148 awards and options

Nil

(f)

Date of the transaction

16 March 2018

(g)

Place of the transaction

Outside a trading venue

 

 

 

This announcement is made in accordance with Article 19.3 of the Market Abuse Regulation.

 

Chris Fussell

General Counsel and Company Secretary

Tel: +44 (0) 20 3058 3546

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHGGUMPWUPRGAQ
Date   Source Headline
19th Apr 20247:00 amRNSDirector/PDMR Shareholding
28th Mar 202411:00 amRNSAdmission of New Shares
12th Mar 20245:55 pmRNSHolding(s) in Company
12th Mar 20244:56 pmRNSHolding(s) in Company
26th Feb 20242:39 pmRNSDirector/PDMR Shareholding
19th Feb 20249:16 amRNSDirectorate Change
19th Feb 20247:00 amRNSStatement re second interim results
16th Feb 20247:00 amRNSDirectorate Change
30th Jan 20247:00 amRNSCFO Appointment
30th Jan 20247:00 amRNSTrading Update
2nd Jan 20247:00 amRNSSanmina Litigation
29th Nov 20231:04 pmRNSSanmina Litigation
7th Nov 20235:40 pmRNSHolding(s) in Company
7th Nov 20235:24 pmRNSHolding(s) in Company
7th Nov 20233:52 pmRNSHolding(s) in Company
1st Nov 202312:03 pmRNSPDMR Shareholding
1st Nov 202311:50 amRNSTotal Voting Rights and Capital
1st Nov 202311:15 amRNSBlock listing Interim Review
31st Oct 20234:32 pmRNSHolding(s) in Company
27th Oct 202312:05 pmRNSResults of General Meeting
4th Oct 202311:52 amRNSCirc re. Related Party Transaction
27th Sep 20237:00 amRNSResult of Equity Issue
26th Sep 20235:07 pmRNSREX Retail Offer
26th Sep 20235:05 pmRNSProposed Placing and Retail Offer
18th Sep 202312:25 pmRNSStatement re Update on Financing
18th Sep 20237:00 amRNSDirector Change
18th Sep 20237:00 amRNSUnaudited Half Year Results 2023
26th Jun 20237:00 amRNSDirectorate Change and Notice of Results
8th Jun 20237:00 amRNSDirector/PDMR Shareholding
7th Jun 20237:00 amRNSDirectorate Changes
16th May 20235:47 pmRNSResult of AGM
16th May 20237:00 amRNSAGM Trading Update
27th Apr 20237:00 amRNSDirector/PDMR Shareholding
17th Apr 20237:00 amRNSDirector/PDMR Shareholding
14th Apr 20231:03 pmRNSDirector/PDMR Shareholding
12th Apr 202312:30 pmRNSNotice of AGM
6th Apr 20232:35 pmRNSTotal Voting Rights
6th Apr 20232:20 pmRNSDirector/PDMR Shareholding
5th Apr 20237:00 amRNSDirectorate Change
3rd Apr 20231:03 pmRNSBlock listing Interim Review
3rd Apr 20237:00 amRNSAnnual Financial Report
30th Mar 20237:00 amRNSDirectorate Change
27th Mar 20237:00 amRNSFinal Results
20th Mar 20237:00 amRNSDirectorate Change
15th Mar 20235:14 pmRNSDirector Declaration
15th Mar 20237:00 amRNSSanmina Litigation
13th Jan 20237:00 amRNSDirectorate Change
13th Jan 20237:00 amRNSTrading Statement
5th Jan 20234:40 pmRNSSecond Price Monitoring Extn
5th Jan 20234:35 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.